Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.

Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group..

Respir Res. 2008 Dec 8;9:78. doi: 10.1186/1465-9921-9-78.

2.

Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?

Carbonell-Estrany X, Fullarton JR, Rodgers-Gray BS, Gooch KL, Vo PG, Figueras-Aloy J.

J Matern Fetal Neonatal Med. 2015 Jul;28(10):1133-41. doi: 10.3109/14767058.2014.947573. Epub 2014 Aug 14.

PMID:
25048748
3.

Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.

Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB; European RSV Risk Factor Study Group..

J Perinat Med. 2010 Jul;38(4):411-7. doi: 10.1515/JPM.2010.074.

PMID:
20297901
4.
5.

Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis.

Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, Gouyon JB, Liese JG.

J Matern Fetal Neonatal Med. 2013 Jun;26(9):926-31. doi: 10.3109/14767058.2013.765850. Epub 2013 Feb 12.

PMID:
23379728
6.

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.

Paes B, Steele S, Janes M, Pinelli J.

Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112.

PMID:
19469698
7.

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.

Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; IRIS Study Group..

Pediatr Infect Dis J. 2008 Sep;27(9):788-93. doi: 10.1097/INF.0b013e3181710990.

PMID:
18664927
8.

European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.

Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M; European RSV Risk Factor Study Group..

J Matern Fetal Neonatal Med. 2011 Jan;24(1):152-7. doi: 10.3109/14767058.2010.482610. Epub 2010 May 21.

PMID:
20486882
10.

Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):891-9. doi: 10.1007/s10096-008-0520-8. Epub 2008 Jul 16. Review.

PMID:
18629558
11.

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61.

PMID:
10632251
12.

Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.

Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF.

Med Decis Making. 2008 Jul-Aug;28(4):471-80. doi: 10.1177/0272989X08315238. Epub 2008 Jun 12.

PMID:
18556643
13.

[Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain].

Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; Grupo IRIS..

An Pediatr (Barc). 2009 Jul;71(1):47-53. doi: 10.1016/j.anpedi.2009.04.010. Epub 2009 Jun 12. Spanish.

14.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group..

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
15.

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons.

Carbonell-Estrany X, Quero J; IRIS Study Group..

Pediatr Infect Dis J. 2001 Sep;20(9):874-9.

PMID:
11734767
16.

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators..

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2703-11. Epub 2012 May 1.

17.

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.

Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH; Munich RSV Study Group..

Eur J Pediatr. 2003 Apr;162(4):230-6. Epub 2003 Mar 1.

PMID:
12647195
18.
19.

Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.

Simoes EA, Carbonell-Estrany X.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S13-8; discussion S18-20.

PMID:
12671448
20.

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D.

Pediatr Infect Dis J. 2004 Sep;23(9):806-14.

PMID:
15361717

Supplemental Content

Support Center